Immix Biopharma (IMMX) Accumulated Expenses (2020 - 2026)

Immix Biopharma has reported Accumulated Expenses for 7 years, with the latest figure at $880671.0 in Q1 2026.

• Quarterly Accumulated Expenses rose 20.34% year-over-year to $880671.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $880671.0 (up 20.34% YoY) and the FY2025 annual result came in at $942163.0, up 627.16% from the prior year.
• Accumulated Expenses declined to $880671.0 in Q1 2026 per IMMX's latest filing, from $942163.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $942163.0 in Q4 2025 and troughed at $9407.0 in Q1 2022.
• A 5-year average of $311351.2 and a median of $170632.0 in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses jumped 4715.87% in 2022, then plunged 76.95% in 2023.
• Over 5 years, Accumulated Expenses stood at $438196.0 in 2022, then slumped by 76.95% to $101007.0 in 2023, then advanced by 28.28% to $129567.0 in 2024, then jumped by 627.16% to $942163.0 in 2025, then retreated by 6.53% to $880671.0 in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $880671.0, $942163.0, and $170896.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.